Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Ho Hong

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|November 11, 2025
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitisMelinda Gooderham, Mahreen Ameen, H Chih-Ho Hong, et al.
The British Journal of Dermatology|October 22, 2024
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up)Jonathan I Silverberg, Christopher G Bunick, H Chih-Ho Hong, et al.
Dermatology and Therapy|June 18, 2021
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 TrialsChristopher Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, et al.
JAMA Dermatology|November 2, 2022
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice GuidelinesSara Mirali, Evan Tang, Aaron M Drucker, et al.
Acta Dermato-Venereologica|April 21, 2023
The Treat-to-Target Project in Atopic Dermatitis: One Year OnMarjolein De Bruin-Weller, Mette Deleuran, Tilo Biedermann, et al.
Lancet (London, England)|July 25, 2022
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trialKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
Dermatology and Therapy|February 12, 2026
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 StudiesAndrew Blauvelt, Leon Kircik, Eric L Simpson, et al.
Immunotherapy|May 31, 2023
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summaryKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Journal of the European Academy of Dermatology and Venereology : JEADV|November 11, 2025
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitisMelinda Gooderham, Mahreen Ameen, H Chih-Ho Hong, et al.
The British Journal of Dermatology|October 22, 2024
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up)Jonathan I Silverberg, Christopher G Bunick, H Chih-Ho Hong, et al.
Dermatology and Therapy|June 18, 2021
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 TrialsChristopher Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, et al.
JAMA Dermatology|November 2, 2022
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice GuidelinesSara Mirali, Evan Tang, Aaron M Drucker, et al.
Acta Dermato-Venereologica|April 21, 2023
The Treat-to-Target Project in Atopic Dermatitis: One Year OnMarjolein De Bruin-Weller, Mette Deleuran, Tilo Biedermann, et al.
Lancet (London, England)|July 25, 2022
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trialKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
Dermatology and Therapy|February 12, 2026
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 StudiesAndrew Blauvelt, Leon Kircik, Eric L Simpson, et al.
Immunotherapy|May 31, 2023
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summaryKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.
The Journal of Allergy and Clinical Immunology|October 4, 2022
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studiesEmma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, et al.
Pageof 10